Anakinra in Infants and Children With Coronary Artery Abnormalities in Acute Kawasaki Disease
Phase: PHASE1
Conditions: Kawasaki Disease
Sponsor: University of California, San Diego

1 
 
 
 
 
 
 
 
 
 
Study Protocol 
 
 
 
 
Anakinra (Kineret®) in Infants and Children  
with Coronary Artery Abnormalities  
in Acute Kawasaki Disease  
 
 
August 13, 2014 
September 10, 2014 
September 22, 2014 
April 14, 2015 
March 4, 2016 
November 10, 2016 
September 20, 2017 
 
 
 
Adriana H. Tremoulet, MD, MAS (PI) 
Jane C. Burns (Co-investigator) 
Brookie Best, PharmD (Pharmacologist) 
Alessandra Franco, MD, PhD (Immunologist) 
Sonia Jain, PhD (Biostatistician) 
Beth Printz, MD (Cardiologist) 
 
 
 

2 
 
 
Table of Contents 
1. 
Introduction .............................................................................................................................................. 4 
2. 
Product name ............................................................................................................................................ 4 
2A. Product name for Phase I/IIa anakinra study ...................................................................................... 4 
2B. Product names for Combination therapy pilot study ........................................................................... 5 
3. 
Chemical name ......................................................................................................................................... 5 
3A. Chemical name for Phase I/IIa anakinra study ................................................................................... 5 
3B. Chemical name for Combination therapy pilot study .......................................................................... 5 
4. 
Proposed indication .................................................................................................................................. 5 
4A. Proposed indication for Phase I/IIa anakinra study ............................................................................ 5 
4B. Proposed indication for Combination therapy pilot study .................................................................... 5 
5. 
Dosage form, route, and dosing regimen .................................................................................................. 5 
5A. Dosage form, route, and dosing regimen for Phase I/IIa anakinra study ............................................ 5 
5B. Dosage form, route, and dosing regimen for Combination therapy pilot study ................................... 5 
6. 
Updated list of investigators at lead site of UC San Diego ...................................................................... 5 
7. 
Study Overview ........................................................................................................................................ 6 
7A. Overall objective ................................................................................................................................. 6 
7B. Hypothesis .......................................................................................................................................... 6 
7C. Study Type ......................................................................................................................................... 7 
7D. Study Population ................................................................................................................................ 7 
7E. Study Duration .................................................................................................................................... 7 
7F. Primary Outcome ................................................................................................................................ 7 
7G. Secondary Outcomes ......................................................................................................................... 7 
8. 
Background & Significance ..................................................................................................................... 8 
8A. Significance ........................................................................................................................................ 8 
8B. Use and safety of anakinra in infants and children ........................................................................... 10 
8C. Safety of atorvastatin in children ...................................................................................................... 11 
8D. Importance of the problem................................................................................................................ 11 
8E. Ongoing KD European clinical trial of anakinra ................................................................................ 11 
8F. Potential to effect change in clinical practice .................................................................................... 12 
8G. Paradigm shift if Specific Aims are achieved ................................................................................... 12 
9. Hypotheses and Specific Aims .................................................................................................................. 12 
9A. Specific Aims for anakinra Phase I/IIa study .................................................................................... 12 
9B. Specific Aims of Combination therapy pilot study ............................................................................. 12 
10.Timeline .................................................................................................................................................... 13 
11. Study design ............................................................................................................................................. 13 
11A. Accrual and Study Duration ............................................................................................................ 13 
11B. Inclusion ......................................................................................................................................... 14 
11C. Exclusion ........................................................................................................................................ 14 
11D. Data Collection ............................................................................................................................... 15 
11E. Laboratory Samples ....................................................................................................................... 16 
11F. Pharmacokinetic Samples (only collected in Phase I/IIa anakinra study) ....................................... 16 
11G. Echocardiography Core Lab for Phase I/IIa anakinra study and Combination therapy pilot 
study ....................................................................................................................................................... 16 
11H. Data Management for Phase I/IIa anakinra study and Combination therapy pilot study ................ 17 
11I. Patient adherence: ........................................................................................................................... 17 
12. Dosing Protocol ....................................................................................................................................... 17 
12A. Dose Levels .................................................................................................................................... 17 
12B. Duration of Study Drug ................................................................................................................... 18 

3 
 
12C. Dose Limiting Toxicity..................................................................................................................... 18 
12D. Dose Escalation for the Phase I/IIa anakinra study ........................................................................ 19 
12E. Maximum Tolerated Dose for Phase I/IIa anakinra study ............................................................... 20 
12F. Stopping Rules ............................................................................................................................... 20 
13. Monitoring Side Effects ........................................................................................................................... 21 
14. Additional Therapy for Phase I/IIa anakinra study and Combination therapy pilot study ...................... 22 
14a. Management of Treatment-resistant Subjects ................................................................................ 22 
14b. Additional Therapy for Coronary Artery Abnormalities .................................................................... 22 
15. Sample Size .............................................................................................................................................. 23 
16. Pharmacokinetic Analysis for Phase I/IIa anakinra study ....................................................................... 23 
17. Immune Monitoring for Phase I/IIa anakinra study ................................................................................. 23 
18. Measures of Activity ................................................................................................................................ 24 
19. Statistical Analyses .................................................................................................................................. 24 
19A. Statistical analysis of safety for Phase I/IIa anakinra study and Combination therapy pilot 
study ....................................................................................................................................................... 24 
19B. Statistical analysis of inflammatory studies .................................................................................... 25 
20. Data and Safety Monitoring ..................................................................................................................... 27 
20A. Data and Safety Monitoring Board (DSMB) for Phase I/IIa anakinra study .................................... 27 
20B. Data and Safety Monitoring Plan (DSMP) for Combination therapy pilot study .............................. 27 
Appendix A: Preparation of Anakinra (Kineret®) in the Hospital for Doses < 20 mg ................................. 28 
References: ..................................................................................................................................................... 29 
 

4 
 
 
1. Introduction 
As of September 7, 2017, the dose escalation study as proposed in this protocol continues to accrue 
subjects at 8 mg/kg/day of anakinra as was approved by the DSMB on February 10, 2017. Thus far, 
anakinra has been well-tolerated and safe without any serious adverse events (SAEs) related to 
study drug. Throughout this protocol, this study is named “Phase I/IIa anakinra study”.  
 
Our recent work has demonstrated that the inflammasome-dependent interleukin (IL)-1 pathway is 
upregulated with increased transcript abundance and levels of proteins including IL-1β and IL-1 
receptor type 1 (IL-1R1) in infants and children with acute KD.(Hoang 2014) In addition, our 
preliminary studies indicate that KD sera induce expression of TIFA (TNF-receptor-associated factor 
[TRAF]-interacting protein with a forkhead-associated [FHA] domain) in endothelial cells (ECs) 
(Figure 1). Notably, TIFA, an upstream activator of NF-κB through IL-1R signaling, has emerged as 
a key mediator in innate immunity and a likely participant in the activation of the NLRP3 (nucleotide-
binding oligomerization domain, leucine rich repeat and pyrin domain containing 3) inflammasome 
leading to IL-1β production.(Ea 2004, Huang 2012, Lin 2016)  
 
However, additional recent work by our group 
has demonstrated that it is not only the blocking 
of the IL-1 pathway that is important to prevent 
coronary artery abnormalities (CAA) in KD. The 
transformation of endothelial cells to a 
myofibroblast phenotype through endothelial-
mesenchymal transition (EndoMT) in the 
coronary artery wall also contributes to 
aneurysm formation. (Shimizu 2013) Statins, 
commonly prescribed as cholesterol-lowering 
agents, have pleotropic effects on vascular ECs that include improving EC function, decreasing 
oxidative stress, and modulating innate and acquired immune responses. (Liao 2005, Oesterle 2017) 
Using an in vitro model with human ECs, we demonstrated that the krüppel-like factor 4 (KLF4)-
microRNA-483 (miR-483) axis is suppressed and markers of EndoMT, including connective tissue 
growth factor (CTGF), are induced following incubation with sera from acute KD patients (Figure 1). 
This effect is reversed when ECs are cultured with sera from atorvastatin-treated KD patients.(He 
2017) Given the pleotropic effects of statins, we conducted a Phase I/IIa, dose-escalation trial of 
atorvastatin for acute KD patients with early CAA (IND # 113304 held by Dr. Jane C. Burns (co-I of 
this proposal); NCT01431105).(Tremoulet 2015) Subject accrual was recently completed for this 
study and atorvastatin was demonstrated to be safe and well-tolerated. In this study of children at 
least 2 years old, the maximum dose in the study (0.75/mg/day up to 80 mg/day) was found to be the 
maximum tolerated dose.  
 
These in vitro data, in combination with the safety of anakinra and atorvastatin in Phase I/IIa, dose-
escalation studies, serve as the motivation to propose a pilot study combining anakinra at 8 
mg/kg/day and atorvastatin at 0.75 mg/kg/day in children with acute KD at least 2 years old who are 
suffering from CAA. Throughout this protocol, this study is referred to as the “Combination therapy 
pilot study”.  
2. Product name  
2A. Product name for Phase I/IIa anakinra study 
Anakinra (Kineret) 
Fig 1. Molecular rationale for anakinra/atorvastatin 
combination therapy 
 
Upregulated during KD (red); downregulated during 
KD (blue) 

5 
 
2B. Product names for Combination therapy pilot study 
Anakinra (Kineret) 
Atorvastatin (Lipitor) 
3. Chemical name  
3A. Chemical name for Phase I/IIa anakinra study 
Recombinant-Methionyl Human Interleukin-1 Receptor Antagonist (r-metHuIL-1ra) 
3B. Chemical name for Combination therapy pilot study 
Recombinant-Methionyl Human Interleukin-1 Receptor Antagonist (r-metHuIL-1ra) 
Atorvastatin 
4. Proposed indication 
4A. Proposed indication for Phase I/IIa anakinra study 
Treatment of infants and children with coronary artery abnormalities from acute KD.  
4B. Proposed indication for Combination therapy pilot study 
 Treatment of children with coronary artery abnormalities from acute KD. 
 
5. Dosage form, route, and dosing regimen 
5A. Dosage form, route, and dosing regimen for Phase I/IIa anakinra study 
Anakinra will be administered first as an intravenous dose and then once or twice daily by 
subcutaneous injection following a pre-determined dose escalation protocol with three dosage levels: 
4 mg/kg, 6 mg/kg, and 8 mg/kg, up to 200 mg. Once the maximum tolerated dose has been 
determined, the initial dose of anakinra will be given subcutaneously as with all subsequent doses.  
5B. Dosage form, route, and dosing regimen for Combination therapy pilot 
study 
Anakinra at 8 mg/kg/day up to a maximum of 200 mg and atorvastatin at 0.75 mg/kg/day up to a 
maximum of 80 mg will be administered as part of a pilot study.  
6. Updated list of investigators at lead site of UC San Diego 
 
Adriana H. Tremoulet, MD, MAS (PI) 
Associate Professor 
Associate Director, Kawasaki Disease Research Center 
Division of Pharmacology and Drug Discovery 
Department of Pediatrics 
University of California, San Diego 
Rady Children’s Hospital San Diego 
 
Jane C. Burns, MD 
Professor 
Director, Kawasaki Disease Research Center 

6 
 
Division of Allergy, Immunology and Rheumatology 
Department of Pediatrics 
University of California, San Diego 
Rady Children’s Hospital San Diego 
 
Brookie Best, PharmD 
Professor of Clinical Pharmacy and Pediatrics 
Division of Pharmacology and Drug Discovery 
Department of Pediatrics 
Skaggs School of Pharmacy 
University of California, San Diego 
 
Alessandra Franco, MD, PhD 
Professor 
Division of Allergy, Immunology and Rheumatology 
Department of Pediatrics 
University of California, San Diego 
 
Sonia Jain, PhD 
Professor 
Co-Director, Biostatistics Research Center 
Division of Biostatistics and Bioinformatics 
Department of Family and Preventive Medicine 
University of California, San Diego 
 
Beth Printz, MD 
Associate Professor of Clinical Pediatrics 
Medical Director, Non-invasive Imaging 
Division of Cardiology 
Department of Pediatrics 
University of California, San Diego 
Rady Children’s Hospital San Diego 
7. Study Overview 
7A. Overall objective  
7A1. Overall objective for Phase I/IIa anakinra study 
The goal of this study is to determine the safety, pharmacokinetics and activity of anakinra in acute 
KD patients with coronary artery Z score ≥ 2.5. The goal will be to find a treatment that could prevent 
or attenuate coronary artery damage in acute KD. 
 
7A2. Overall objective for Combination therapy pilot study 
The goal of this study is to determine the safety and activity of these two drugs in combination in 
acute KD patients with coronary artery Z score ≥ 2.5. The goal will be to find a treatment regimen that 
could prevent or attenuate coronary artery damage in acute KD.  
7B. Hypothesis  
7B1. Hypothesis for Phase I/IIa anakinra study 
We postulate that anakinra will be safe in infants and children with acute KD.  
 
7B2. Hypothesis for Combination therapy pilot study 

7 
 
We postulate that anakinra and atorvastatin in combination will be safe in children with acute KD. We 
also postulate that this combination therapy will reduce inflammation in children with acute KD more 
than using anakinra or atorvastatin alone.    
7C. Study Type 
7C1. Hypothesis for Phase I/IIa anakinra study 
This is a Phase I/IIa, dose escalation study.  
 
7C2. Hypothesis for Combination therapy pilot study 
This is a pilot study. 
7D. Study Population  
7D1. Study population for Phase I/IIa anakinra study 
Infants and children with acute KD who have a Z-score ≥ 2.5 of the left anterior descending (LAD) or 
right coronary arteries (RCA). 
 
7D2. Study population for Combination therapy pilot study 
Children with acute KD who have a Z-score ≥ 2.5 of the LAD or RCA. 
7E. Study Duration 
7E1. Study duration for Phase I/IIa anakinra study 
The entire study will last 5 years. Each subject will be in the study for 6 weeks.   
 
7E2. Study duration for Combination therapy pilot study 
The entire study will last 5 years. Each subject will be in the study for 6 weeks.  
7F. Primary Outcome  
7F1. Primary Outcome for Phase I/IIa anakinra study 
Safety of anakinra in the study population 
 
7F2. Primary Outcome for Combination therapy pilot study 
Safety of anakinra and atorvastatin in combination  
7G. Secondary Outcomes  
7G1. Secondary Outcomes for Phase I/IIa anakinra study 
1. Pharmacokinetics of anakinra 
2. Immune-monitoring pre-and post-therapy 
a. Enumeration of myeloid dendritic cell populations 
b. Enumeration of activated CD4+ and CD8+ DR+ T cells, enumeration regulatory T cells 
3. Measures of inflammation pre-and post-therapy 
a. Transcript abundance changes over time by RNAseq 
b. Levels of high sensitivity (hs) C-reactive P (CRP), alpha-1 antitrypsin, TNFaR1 and R2, 
IFNg, IL-1 RAP, IL-1R1 and R2, MMP9, caspase-1, IL-6R, IL-18RAP, IL-12, IL-2, TGFb 
and IL-10  
4. Echocardiographic assessment of coronary artery internal diameters expressed as Z scores 
pre-and post-therapy  
 
7G2. Secondary Outcomes for Combination therapy pilot study 
1. Measures of inflammation 
a. Plasma levels of IL-1R accessory protein, soluble IL-1R1, IL-17, IL-6, sIL-6R, 
TNFαR1, IFNγ, IL-10, and MMP9 

8 
 
b. Transcript abundance changes over time by RNAseq of the above analytes  
2. Endothelial cell function studies to evaluate for suppression of the innate immune response 
by anakinra and restoration of EC function by atorvastatin.  
3. Echocardiographic assessment of coronary artery internal diameters expressed as Z scores 
 
8. Background & Significance 
8A. Significance 
Kawasaki Disease (KD), the 
most common cause of 
acquired heart disease in 
children in Western 
developed countries and 
Asia, is a systemic vasculitis 
of unknown etiology. In the 
United States, there are at 
least 5-6,000 new cases 
each year (Kaneko 2011). 
However, without a specific 
diagnostic test, the true 
burden of disease is 
unknown. At Rady Children’s 
Hospital San Diego, we 
cared for over 85 new KD 
patients in 2013 and follow 
over 1,200 families in our 
outpatient KD Clinic (350 
outpatient visits/year), of 
whom 9% developed 
aneurysms and 25% 
developed dilated coronary 
arteries. In Japan, the 
country of highest incidence 
(>215/100,000 children < 5 
yrs.), there are more than 
12,000 new cases each year 
and rates continue to rise 
(Nakamura 2010). KD 
causes both a myocarditis 
and a vasculitis that 
damages the coronary 
arteries and other medium-
sized muscular arteries 
(Yutani 1980, Yonesaka 
1989). The major sequelae 
of aneurysms include 
thrombosis, late coronary 
artery stenosis, myocardial 
ischemia, myocardial 
infarction, and death (Kato 
Figure 2. IL1signaling pathway was the key upregulated pathway in 
acute KD 
 
A) Transcripts involved in IL1 signaling pathways were more 
abundant in acute KD; differentially abundant transcripts between 
acute and convalescent KD samples are highlighted in red. B) and 
C) IL1R1 and IL1receptor associated protein (RAP) were 
differentially expressed only in acute vs. convalescent KD but not in 
other diseases. ** P value < 0.01 

9 
 
1996, Gordon 2009). Clearly, aneurysm prevention is a primary goal of treatment during the 
acute phase of the disease, which leads us to focus on treatment of patients with early signs 
of coronary artery abnormalities (CAAs) in this pilot study. 
 
Intravenous immunoglobulin (IVIG) in combination with aspirin is the only approved therapy for KD. 
The major acute risk of aneurysm formation is thrombosis, which can be prevented with systemic 
anti-coagulation with warfarin or enoxaparin in addition to antiplatelet therapy with aspirin or 
clopidogrel in patients with large aneurysms (>6 mm). However, there is no recommended therapy 
to halt the progression of arterial wall destruction and prevent aneurysm formation beyond 
the initial dose of IVIG.  
 
 
8A1. Role of IL-1 pathway in KD and blockade by anakinra  
In KD, the IL-1 pathway is upregulated, as demonstrated by increased transcript abundance by 
microarray and by increased levels of pathway proteins in the plasma (Maury 1988, Leung 1989, 
Popper 2007, Hoang 2014). (Figure 2 and Table 1) 
 
 
Table 1. Comparison of the gene pathway analysis of up-regulated pathways in each group of patients 
Most abundant transcripts for the top upregulated pathways (KD acute vs. conv., other groups vs. healthy 
controls) and shared among KD, viral and bacterial infection groups. Pathways are ordered by descending 
log (p-value). Individual probe P values are uncorrected. Yellow highlighting identifies transcripts that were 
significant in more than one pathway. Red box identifies transcripts in the IL-1 pathway.  
 
Furthermore, in the Lactobacillus casei cell wall extract mouse model that develops a KD-like 
coronary arteritis, the IL-1 receptor antagonist, anakinra, prevented the development of coronary 
lesions, as did knocking out the IL-1 receptor (Lee 2012). Anakinra has been used to treat a severe 
KD patient who was non-responsive to IVIG treatment (Cohen 2012).Treatment with anakinra was 
safe and coincided with a decrease in systemic and coronary artery inflammation. The proposed 
study will determine if anakinra is safe to use in young children with KD and has 
demonstrable anti-inflammatory activity at a well-tolerated dose. Assessments of drug activity 
will allow us to determine appropriate end-points for a future Phase III study to address the 
efficacy of anakinra in attenuating vascular wall damage and preventing aneurysms in KD 
patients.  
 

10 
 
8B. Use and safety of anakinra in infants and children 
Anakinra is currently used in several inflammatory diseases in infants and children, including 
systemic juvenile idiopathic arthritis and the autoinflammatory syndromes known as cryopyrin-
associated periodic syndromes (CAPS)(Hoffman 2009, Ringold 2013). In a recent study of 26 
patients with the autoinflammatory syndrome neonatal-onset multisystem inflammatory disease 
(NOMID), treatment with anakinra for 36 months had a low adverse event rate, with upper respiratory 
infection as the most commonly reported complication (Sibley 2012). A similar study using anakinra 
in another CAPS, Muckle Wells syndrome, did not demonstrate any SAEs in the 12 patients treated 
with anakinra, of whom 5 were children (Kuemmerle-Deschner 2011). Two case reports have been 
published reporting the use of anakinra in children with refractory, acute KD. A 2 year old with giant 
aneurysms who failed therapy with IVIG and steroids and developed giant aneurysms was treated 
with a 6 week course of anakinra at 1 mg/kg (Cohen 2012). He suffered no adverse effects and at 6 
months coronary angiography demonstrated resolution of the aneurysms, which was unexpected in 
such a severe case of KD. An 11 week old with KD and giant aneurysms was refractory to three 
doses of IVIG, steroids and a dose of infliximab (Shafferman 2014). She was treated with anakinra 
initially at 6 mg/kg/day and then increased to 9 mg/kg/day. She too did not suffer any adverse effects 
and at an 8 month follow up visit her coronary artery status had also significantly improved.   
 
Given that this medication is administered once daily as a subcutaneous injection, the most common 
adverse reaction is irritation at the injection site. Table 2 is a summary of published and unpublished 
data on the use of anakinra in children <2 years old: 
 
Table 2. Use of anakinra in children < 2 years old 
Ages Treated  
(in months) 
Max Dose 
(mg/kg) 
Diagnosis 
Reference 
17 
1.6 
CINCA 
(Matsubara 2006) 
3 and 4 
6 & 10 
NOMID 
(Neven 2010) 
2,4,13 and 22 
1-4 
DIRA 
(Aksentijevich 2009) 
1 
1 
DIRA 
(Stenerson 2011) 
8 
11 
sJIA 
(Record 2011) 
10 and 18 
2-4 
sJIA 
(Nigrovic 2011) 
5 
3 
DIRA 
(Minkis 2012) 
10, 13, 16, 20 
2-4 
NOMID 
(Sibley 2012) 
18 
8 
MVK 
(Ruiz Gomez 2012) 
24 
9 
KD 
(Cohen 2012) 
6 
2-4 
Def IL-36Ra 
(Rossi-Semerano 2013) 
8 
2-10 
sJIA  
(Urien 2013) 
3 and 14 
2-3 
MVK 
(Levy 2013) 
6 
2 
NOMID 
(Montealegre 2014) 
2 
9 
KD & MAS 
(Shafferman 2014) 
12 and 15 
6 & 8 
CAPS 
(Hoffman 2014) 
18 
15 
sJIA & MAS 
(Cartwright 2014) 
11 
8 
CAPS 
(Jerath 2014) 
13** 
4 
sJIA 
(Momborquette 2014) 
15 and 18 
3.5 & 4 
CINCA & sJIA 
(Guedes 2014) 
8, 10, 15, 17, and 22  
1 to 9  
sJIA 
(Punaro 2014) 
6, 9 and 15 
1-3 
CAPS 
(Ombrello 2014) 
20 
5 
Hyper IgD Syndrome 
(Ombrello 2014) 

11 
 
CINCA = chronic infantile, neurological, cutaneous and arthritis; NOMID = neonatal onset multi-system 
inflammatory syndrome (CINCA and NOMID are the same syndrome); DIRA = deficiency of the IL-1 
receptor antagonist; sJIA = systemic juvenile idiopathic arthritis; MVK = mevalonate kinase deficiency; 
KD = Kawasaki disease; MAS = macrophage activation syndrome; CAPS = cryopyrin associated 
periodic syndrome 
 
No adverse effects noted besides mild local reaction unless otherwise noted; **coxsackie virus while 
also on methotrexate and steroids;  
 
Thus, at least 39 children < 2 years of age, and as young as 2 months of age, have been treated with 
anakinra with doses ranging from 1 to 15 mg/kg.  
8C. Safety of atorvastatin in children 
The safety of atorvastatin in children as young as 2 years of age with acute KD was assessed in a 
Phase I/IIa dose escalation study (IND 113304 issued to Dr. Jane C. Burns, co-investigator of this 
study). On May 19, 2016, the DSMB for this Phase I/IIa study evaluated the data from the Phase I 
dose-escalation study of atorvastatin for 6 weeks in children at least 2 years with acute KD and 
coronary artery damage. The DSMB determined that a 6 week course of atorvastatin was safe and 
well-tolerated in children ≥ 2 years with acute KD. In addition, based on the review of the safety of the 
Phase I study, the DSMB determined 0.75 mg/kg/day of atorvastatin to be the maximum tolerated 
dose. An additional 10 subjects were enrolled at 0.75 mg/kg/day as part of the dose expansion cohort 
study and further demonstrated the safety and tolerability of this dose in acute KD.  The level of the 
cholesterol brain metabolite, 24-OH cholesterol, was measured in both statin-treated KD patients and 
in those treated with standard therapy for KD. No significant difference was found between the 
groups in the levels of 24-OH cholesterol, further demonstrating the safety of atorvastatin in acute KD 
as it does not reduce the levels of 24-OH cholesterol, which are important for normal brain 
development.  
 
On August 1, 2017, this original Phase I/IIa dose-escalation and expansion cohort study was 
completed. On August 4, 2017, an annual report of the atorvastatin IND was sent to the FDA 
demonstrating that there had been no unexpected, adverse events in this study and that atorvastatin 
was safe and well-tolerated. An abstract reporting the results of the Phase I study has been accepted 
for poster presentation at the American Heart Association in November 2017.  
8D. Importance of the problem 
Once aneurysms have formed, there is no way to turn back the biologic clock and undo them. The 
transmural inflammation destroys the normal architecture and even in children who remodel the 
aneurysm to form a more normal lumen, the vessel is never functionally normal again. The 
remodeled segment cannot dilate normally during increased myocardial oxygen demand and thus 
serves as a functional stenosis. It has been estimated that there are currently over 24,000 young 
adults in the United States with a history of KD, including over 8,000 with a history of coronary artery 
abnormalities. Without a new therapeutic approach this number is expected to grow by 1,400 
individuals each year (Gordon 2009). A recent study found that over 5% of all young adults (<40 
years) evaluated by cardiac catheterization for suspected myocardial ischemia have aneurysms 
compatible with antecedent KD (Daniels 2012). 
8E. Ongoing KD European clinical trial of anakinra 
Sobi Pharmaceuticals, the manufacturer of Kineret® (anakinra), is currently supporting a clinical trial 
in Europe, treating IVIG-resistant KD patients (≥ 8 months of age) with a 14-day course of anakinra. 
In this trial, there will be within-subject dose escalation starting at 2mg/kg and increasing every 24h 
through 4 mg/kg and 6 mg/kg based on persistence of fever.  

12 
 
8F. Potential to effect change in clinical practice 
8F1. Potential of Phase I/IIa anakinra trial to effect change in clinical practice 
The current clinical practice is to give every patient the same standard therapy (IVIG 2g/kg with 
aspirin 30-50/kg) and to monitor for CAA. In the unfortunate child who carries the genetic risk for 
CAA, no intervention to modify vessel wall inflammation is currently recommended (Newburger 
2004).  
 
In a recent article entitled “Mining for therapeutic gold”, Director of the NIH, Dr. Francis Collins, stated 
that “repurposing” therapeutics should be a strategy “to translate research into clinically useful 
products” (Collins 2011). Our goal is to translate our findings on the role of the IL-1 pathway in acute 
KD and “repurpose” anakinra to test the hypothesis that the anti-inflammatory properties of this drug 
will prevent or attenuate coronary artery aneurysms in infants and children with KD.  
 
 
 
8F2. Potential of Combination therapy pilot study to effect change in clinical practice  
Our goal is to translate our findings on the role of the IL-1 pathway and EndoMT in acute KD and 
“repurpose” anakinra and atorvastatin in combination to test the hypothesis that the anti-inflammatory 
properties of these drugs in combination will prevent or attenuate coronary artery aneurysms in 
children with KD.  
8G. Paradigm shift if Specific Aims are achieved 
By performing this study, we will bring to the forefront the need for new therapies for the subset of KD 
patients who are genetically predisposed to develop coronary artery damage. The paradigm shift will 
be to intensify initial therapy for KD patients, thus acknowledging the urgency of early intervention to 
prevent the permanent disability associated with aneurysm formation. Furthermore, given the unique 
immunological expertise within our group, demonstration of the immunomodulatory effects in a 
cardiovascular disease could pose a novel treatment for other cardiovascular diseases. 
9. Hypotheses and Specific Aims 
9A. Specific Aims for anakinra Phase I/IIa study 
 
Specific Aim 1 will test the hypothesis that a 2-6-week course of anakinra will be safe and 
well-tolerated in infants and children with acute KD who have a Z-score ≥ 2.5 of the LAD or 
RCA. 
 
The safety of anakinra will be assessed by monitoring for leukopenia, clinical and laboratory signs of 
infection, and injection site reactions.  
 
Specific Aim 2 will describe the pharmacokinetics of anakinra and test the hypothesis that 
anakinra will decrease systemic and coronary artery inflammation associated with acute KD. 
 
Blood will be tested pre-drug administration, 48 hours after initiation of therapy and at 2 weeks and 6 
weeks for markers of inflammation and enumeration of dendritic cells and T cells.  Echocardiographic 
assessment of CAA at these time points will be compared to historical controls matched for age, sex, 
illness day at diagnosis, and coronary artery status on initial echo. 
9B. Specific Aims of Combination therapy pilot study 
 

13 
 
Specific Aim 1 will test the hypothesis that a 2 to 6 week course of anakinra and atorvastatin 
in combination will be safe and well-tolerated in children with acute KD who have a Z-score of 
≥2.5 of LAD or RCA.  
 
While the safety of anakinra will be assessed by monitoring for leukopenia, infection and injection site 
reactions, the safety of atorvastatin will be assessed by monitoring for liver and muscle toxicity as 
well as total and 24-OH cholesterol levels.  
 
Specific Aim 2 will test the hypothesis that a combination of anakinra and atorvastatin therapy 
will decrease systemic inflammation and restore endothelial cell dysfunction.  
 
Cytokine levels and matrix metalloproteinase activity in sera and transcript abundance in whole blood 
RNA will be measured pre- and post-treatment. These sera will also be tested in vitro with cultured 
endothelial cells with read-outs for innate immune signaling pathways and endothelial to 
mesenchymal transition (EndoMT).  
10.Timeline 
 
 
11. Study design  
 
11A. Accrual and Study Duration 
11A1. Accrual and study duration for Phase I/IIa anakinra study 
We estimate enrolling 0-2 patients per month at the two research sites over the course of a year with 
a target enrollment of 30 patients over a 4 year period. All subjects enrolled will be in the study for up 
to 6 weeks during which time they will receive once or twice daily subcutaneous injections of 
anakinra administered by the parents at home. 
 
11A2. Accrual and study duration for Combination therapy pilot study 
We estimate enrolling 0-2 patients every 6 months with a target enrollment of 10 patients over a 5-
year period. All subjects enrolled will be in the study for up to 6 weeks during which time they will 
Table 3. Timeline of studies 
Study and Task 
2015 
2016 
2017 
2018 
2019 
2020 
2021 
2022 
Phase I/IIa anakinra study 
 
 
 
 
 
 
 
 
• 
Spec Aim1: Safety/ 
tolerability/dose escalation  
 
 
 
 
 
 
 
 
• 
Spec Aim 2: PK & Anti-
inflammatory Studies 
 
 
 
 
 
 
 
 
• 
Data analysis and manuscript 
preparation 
 
 
 
 
 
 
 
 
Combination therapy pilot study 
 
 
 
 
 
 
 
 
• 
IND amendment and IRB 
approval 
 
 
 
 
 
 
 
 
• 
Spec Aim 1: Safety/tolerability 
 
 
 
 
 
 
 
 
• 
Spec Aim 2: Anti-inflammatory 
studies 
 
 
 
 
 
 
 
 
• 
Data analysis and manuscript 
preparation 
 
 
 
 
 
 
 
 

14 
 
receive once or twice daily subcutaneous injections of anakinra and once daily oral administration of 
atorvastatin administered by the parents at home.  
11B. Inclusion 
 
11B1. Inclusion for Phase I/IIa anakinra study 
1. Meets clinical criteria for KD according to American Heart Association guidelines (Table 4): 
Fever (T≥38oC or 100.4oC)  ≥ 3 days and ≥ 2 clinical criteria with LAD or RCA  z-score ≥ 2.5  
2. Patient is at least 28 days old 
3. Patient presents within the first 20 days after fever onset  
4. Parent or legal guardian able and willing to provide informed consent  
5. Able to be dosed between 20 mg (min amount on syringe) and 200 mg at 8 mg/kg/day 
 
Dose escalation level* 
Minimum subject weight to 
administer 20 mg 
Maximum subject weight to 
administer 200 mg 
8 mg/kg 
2.5 kg 
25 kg 
*This table includes only the 8 mg/kg dose level as enrollment in the 4 and 6 mg/kg cohorts 
has been completed as of the Nov 2016 revision.  
*As of the August 2017 revision, we have enrolled 2 subjects at 8mg/kg/day without any dose 
limiting toxicities. 
 
11B2. Inclusion for Combination therapy pilot study 
 
1. Meets clinical criteria for KD according to American Heart Association guidelines (Table 4): 
Fever (T≥38oC or 100.4oC)  ≥ 3 days and ≥ 2 clinical criteria with LAD or RCA z-score ≥ 2.5  
2. Patient at least 2yo and weighs ≤ 25 kg (weight limit based on anakinra max dose of 200 
mg/day at a calculated dose of 8 mg/kg/day) 
3. Patient presents within the first 20 days after fever onset  
4. Parent or legal guardian able and willing to provide informed consent  
 
Table 4. Diagnostic criteria for KD with CAA (Adapted from American Heart Association 
(Newburger 2004)):  
KD standard clinical criteria : 
• 
Bilateral conjunctival injection 
• 
Changes of the mucous membranes of the upper respiratory tract: injected pharynx, 
injected, fissured lips, strawberry tongue 
• 
Changes of the peripheral extremities: peripheral edema, peripheral erythema, 
periungual desquamation 
• 
Polymorphous rash 
• 
Cervical adenopathy >1.5 cm 
11C. Exclusion 
11C1. Exclusion for Phase I/IIa anakinra study 
1. Use of an IL-1beta antagonist within the 3 months prior to enrollment 
2. Have any chronic disease, except asthma, atopic dermatitis, autism or controlled seizure 
disorder  
3.  Patient has a history of hypersensitivity to anakinra  
4. Personal or immediate family history of tuberculosis (TB) or TB exposure 
5. Active, culture-positive bacterial infection 
6. Baseline Scr ≥ 0.50 mg/dL (28 days old to 1 year old) or an eGFR lower than 45 
mL/min/1.73m2 (≥ 1 year old) 
 

15 
 
11C2. Exclusion for Combination therapy pilot study 
1. Use of an IL-1beta antagonist within the 3 months prior to enrollment 
2. Have any chronic disease, except asthma, atopic dermatitis, autism or controlled seizure 
disorder  
3. History of hypersensitivity to anakinra  
4. Personal or immediate family history of tuberculosis (TB) or TB exposure 
5. Active, culture-positive bacterial infection 
6. Baseline eGFR lower than 45 mL/min/1.73m2 (as subjects ≥ 1 year old) 
7. Use of a statin, fibrate, or niacin within the 3 months prior to enrollment 
8. Screening creatine phosphokinase (CK) ≥ 3x upper limit of normal for age 
9. Taking a CYP3A4 inhibitor (i.e. cyclosporine, clarithromycin or doxycycline) in the last 7 days 
10. History of allergy to atorvastatin or its derivatives 
11D. Data Collection 
11D1. Data collection for Phase I/IIa anakinra study 
1. Demographic data:  
a. Patient's age at KD onset, sex, self-reported ethnicity of each biologic parent  
2. Clinical data:  
a. Physical findings confirming the KD case definition(Newburger 2004) 
b. Illness day at study entry 
c. Response to IVIG (IVIG-resistance will be defined as persistent or recrudescent fever 
(T≥38.0˚C rectally) ≥36 h and < 7d following the end of the IVIG infusion (2g/kg) 
(Tremoulet 2008). 
d. Name, dose and indication of concomitant medications taken while on study 
e. Complete white blood count (WBC), hsCRP, erythrocyte sedimentation (ESR), fibrinogen, 
and alpha-1-antitrypsin levels at baseline, 48 hours (not ESR as IVIG recently 
administered), 2 weeks and 6 weeks (if still on study drug)  after drug administration  
f. 
Serum creatinine at baseline prior to receiving study drug 
g. Severity and duration of infections (with any associated cultures or diagnostic testing) 
during study 
h. Echocardiographic data at baseline, 48 hours, and 2 and 6 weeks (standard of care for 
patients with CAA) 
 
11D2. Data collection for Combination therapy pilot study 
1. Demographic data:  
a. Patient's age at KD onset, sex, self-reported ethnicity of each biologic parent  
2. Clinical data:  
a. Physical findings confirming the KD case definition (Newburger 2004) 
b. Illness day at study entry 
c. Response to IVIG (IVIG-resistance will be defined as persistent or recrudescent fever 
(T≥38.0˚C rectally) ≥36 h and < 7d following the end of the IVIG infusion (2g/kg) 
(Tremoulet 2008). 
d. Name, dose and indication of concomitant medications taken while on study 
e. Serum creatinine at baseline prior to receiving study drug 
f. 
Severity and duration of infections (with any associated cultures or diagnostic testing) 
during study 
g. Complete blood count, CRP, hsCRP, ESR, aspartate aminotransferase (AST), and ALT at 
baseline, 48 hours (not ESR as IVIG recently administered), and 2 and 6 weeks  
h. CK and fasting lipid panel at baseline (after enrollment), 48 hours, and 2 and 6 weeks (if 
still on study drug) 
i. 
Echocardiographic data at baseline, 48 hours, and 2 and 6 weeks (standard of care for 
patients with CAA) 

16 
 
11E. Laboratory Samples 
11E1. Laboratory samples for Phase I/IIa anakinra study 
Subjects will have the following samples collected at baseline (pre- anakinra), 48 hours and 2 
and up to 6 weeks (if still on study drug) (+/- 7 days) from enrollment: 
1. RNA collection: Whole blood RNA will be collected using PAX gene tubes. RNA will be isolated 
according to the manufacturer’s instructions and aliquoted and stored at -80°C.  
2. Plasma, serum, and heparinized whole blood collection: EDTA plasma and serum will be 
collected for measures of inflammation. Whole blood (5 ml in large green top) in a sodium heparin 
tube will be collected for T cell subset and cytokine studies. 
 
11E2. Laboratory samples for Combination therapy pilot study 
Subjects will have the following samples collected at baseline (pre- anakinra and -
atorvastatin), 48 hours and 2 and up to 6 weeks (if still on study drug) (+/- 7 days) from 
enrollment: 
1. RNA collection: Whole blood RNA will be collected using PAX gene tubes. RNA will be isolated 
according to the manufacturer’s instructions and aliquoted and stored at -80°C.  
2. Plasma and serum: EDTA plasma and serum will be collected for measures of inflammation.  
11F. Pharmacokinetic Samples (only collected in Phase I/IIa anakinra study) 
• 
Dosing history (dates, times and amounts of doses) 
• 
Height and weight on day of PK sampling 
• 
Dates and times PK samples drawn 
• 
PK samples around initial half of the 1st dose will be drawn during the following sample windows  
1. 1-3 hours after the dose 
2. 4-6 hours after the dose 
3. 7-9 hours after the dose, prior to administration of the second half of the dose at 12 
hours 
• 
Trough samples 48 hours, and 2 and 6 weeks after the start of the first dose  
11G. Echocardiography Core Lab for Phase I/IIa anakinra study and 
Combination therapy pilot study 
An echocardiogram will be performed at the following time points:  
• 
During initial hospitalization (as soon after admission as possible) 
• 
48 hours after enrollment in this study 
• 
Study week 2 (Study day 14 ± 7 days)  
• 
Study week 6 (Study day 42 ± 7 days) 
 
2-D transthoracic echocardiograms (2-D Echo) will be performed on all KD subjects according to a 
strict pre-determined protocol at standard of care time points. All echocardiographic images will be 
analyzed by Dr. Beth Printz, Director of Non-Invasive Cardiovascular Imaging at Rady Children’s 
Hospital San Diego. She will be blinded to patient data and clinical status. Dr. Printz will also assure 
adherence to the echo protocols across all echocardiogram technicians. 2-D Echo will be performed 
at KD diagnosis (within 24h of IVIG infusion) and again at two and six weeks following enrollment 
with sedation when clinically indicated. The internal lumen diameters of the left main (LMCA), 
proximal and distal LAD, circumflex, posterior descending, and proximal and distal RCA will each be 
measured.  Dimensions of the LMCA, proximal LAD, and proximal RCA will be adjusted for body 
surface area and expressed in standard deviation units (Z-scores) (Manlhiot 2009). A variable “Z 
worst any vessel” will be created to capture the maximal Z score of the RCA or LAD at any time 
point, as well as the Z-score of the LMCA if an aneurysm is present there with a Z-score larger than 
that of the RCA or LAD. Coronary artery aneurysm will be defined as a Z-score of 2.5 or larger of the 
RCA or LAD(Nishiike 2006).  
 

17 
 
Additional echocardiographic data will be collected to assess aortic root dimensions and left 
ventricular dimensions and function, including indices of diastolic ventricular function (mitral inflow 
Doppler and tissue Doppler imaging), as recent reports have demonstrated abnormalities in each of 
these parameters following acute KD (Kato , Printz) Aortic root and ventricular dimensions and 
function will be expressed as body surface area (BSA)- or age-adjusted Z scores. A dilated aortic 
sinus diameter will be defined as a BSA-adjusted Z score ≥ 2.0 (Ravekes 2001). LV systolic 
dysfunction will be defined as an age-adjusted LV fractional shortening Z score < -2; LV diastolic 
dysfunction will be defined as an abnormal age-adjusted mitral inflow Doppler E’-wave, E’/A’ ratio, or 
mitral deceleration time according to published normative data (Chaudhuri).  
11H. Data Management for Phase I/IIa anakinra study and Combination 
therapy pilot study 
Subjects will be assigned a unique study number. Demographic and clinical information including all 
numerical echo data parameters will be entered into an established, password-protected, database in 
use by our research group since 2001 (http://www-pediatrics.ucsd.edu/kawasaki) that currently 
contains data on over 1,200 KD subjects. The web portal uses the secure web application Research 
Electronic Data Capture (REDCap) (Harris 2009). 
11I. Patient adherence:  
11I1. Patient adherence for Phase I/IIa anakinra study 
Remaining syringes of anakinra will be counted at the 2 and 6 week visits to assess patient 
adherence. 
 
11I2. Patient adherence for Combination therapy pilot study 
Remaining syringes of anakinra and tablets of atorvastatin will be counted at the 2 and 6 week visits 
to assess patient adherence. 
12. Dosing Protocol 
12A. Dose Levels  
12A1. Dosing for Phase I/IIa anakinra study 
All subjects will be treated with IVIG (2g/kg) and aspirin (30-50 mg/kg/day divided every 6 hours; 
lowered to 3-5 mg/kg/day once sent home), which is the standard of care. In order to minimize the 
pain from subcutaneous injections, the first two doses of anakinra have been administered 
intravenously and divided every 12 hours for the dose escalation part of the study (i.e. 4 mg/kg/day is 
2 mg/kg every 12 hours for two doses). As has been published in the peer-reviewed literature, we 
administered the dose by bolus over a 1 to 3 minute period (Opal 1997). As anakinra is formulated 
for intravenous administration, dilution is not necessary prior to administration.  The unused material 
is discarded in a medical waste container after each administration. See Appendix A for details 
regarding preparation of the study drug for administration of less than 20 mg.  
All subsequent doses are administered subcutaneously starting 24 hours after the first dose of the 
medication. This study has 3 dose levels (4 mg/kg/day, 6 mg/kg/day, and 8 mg/kg/day), with a 
maximum dosage of 200 mg daily (Table 5).   
 
If the daily dose of anakinra for a subject is ≤ 100mg, then the subject will receive a subcutaneous 
injection of anakinra once daily. If the daily dose of anakinra is greater than 100 mg (with a max dose 
of 200 mg daily), then the dose will be split in half with administration subcutaneously every 12 hours 
(i.e. a total daily dose of 150 mg will be administered as 75 mg subcutaneously every 12 hours).  
 
 
 

18 
 
Table 5. Dose Levels 
Dose Cohort 
Dose Level 
Number of Subjects  
1 
4 mg/kg/day 
3-6 
2 
6 mg/kg/day 
3-6 
3 
8 mg/kg/day 
3-6 
TOTAL 
9-18 
 
Due to anakinra's predominant renal clearance, its dose is reduced in adults with significant renal 
dysfunction, 30mL/min (30% of normal adults).  Given immaturity in renal function of infants, no 
infants will be enrolled during the first 4 weeks of life.   At the age of 4 weeks, the typical GFR for a 
term infant is approximately 1.5 mL/min/kg (Rhodin et al. Pediatr Nephrol. 2009 Jan;24(1):67-76.).  
This represents 40-45% of the mature adult value (allometrically scaled), or approximately 50% 
above the threshold for dose reduction due to renal dysfunction in adults (45 mL/min/1.73m2).  We 
will require that individual study participant infants have renal function significantly better than eGFR 
of 30 mL/min/1.73m2.  At 4 weeks of age, the original infant Schwartz equation predicts a eGFR of 35 
mL/min/1.73m2 with a serum creatinine of 0.7 mg/dL.  To provide an additional safety buffer and 
account for more specific creatinine assay in use today, we will only enroll infants with screening Scr 
≤ 0.50 mg/dL, approximately equivalent to an eGFR of 45 mL/min/1.73m2. For children ≥ 1 year of 
age who may be eligible for enrollment based on weight, higher Scr will be acceptable as long as the 
eGFR remains at least 45 mL/min/1.73m2. Calculations will be made with the widely accepted 
modified Schwartz equation (http://www.globalrph.com/specialpop.htm). As we do not expect renal 
abnormalities to occur with KD or because of anakinra, Scr will only be assessed at baseline.  
 
12A2. Dosing for Combination therapy pilot study 
All subjects will be treated with IVIG (2g/kg) and aspirin (30-50 mg/kg/day divided every 6 hours; 
lowered to 3-5 mg/kg/day once sent home), which is the standard of care.  
Anakinra will be administered once or twice daily subcutaneously at 8 mg/kg/day with a maximum 
dose of 200 mg/day. If the daily dose of anakinra for a subject is ≤ 100mg, then the subject will 
receive a subcutaneous injection of anakinra once daily. If the daily dose of anakinra is greater than 
100 mg (with a max dose of 200 mg daily), then the dose will be split in half with administration 
subcutaneously every 12 hours (i.e. a total daily dose of 150 mg will be administered as 75 mg 
subcutaneously every 12 hours).  
 
Atorvastatin will be administered orally once daily at 0.75 mg/kg/day with a maximum dose of 80 
mg/day.  
12B. Duration of Study Drug 
12B1. Duration of study drug for Phase I/IIa anakinra study 
All subjects will receive 2 weeks of therapy. Subjects with an echo at 2 weeks that shows either a 
LAD or RCA z-score ≥ 2.0 will receive an additional 4 weeks of therapy to complete a total course of 
6 weeks. All subjects will remain on study for the full 6 weeks whether or not they are receiving 
anakinra. 
 
12B2. Duration of study drug for Combination therapy pilot study 
All subjects will receive 2 weeks of therapy. Subjects with an echo at 2 weeks that shows either a 
LAD or RCA z-score ≥ 2.0 will receive an additional 4 weeks of therapy to complete a total course of 
6 weeks. All subjects will remain on study for the full 6 weeks whether or not they are receiving 
anakinra and atorvastatin. 
12C. Dose Limiting Toxicity/Adverse Drug Toxicity 
12C1. Dose limiting toxicity for Phase I/IIa anakinra study 
Dose Limiting Toxicity (DLT) will be defined as any of the following at the 2 or 6 week time point: 

19 
 
• 
Serious infection qualifying as an SAE (see Section 12) and requiring intervention  
• 
A decrease in the white blood cell count (WBC) to <1500/mm3 (Grade 3 severity by 
NIH/NIAID) (NIH 2009) 
• 
An anaphylactoid reaction to an injection of anakinra 
 
A low absolute neutrophil count (ANC) is considered part of the natural course of KD and usually 
occurs 2 weeks after the initial illness (Tremoulet 2011). Given this, a low ANC will not be considered 
a DLT or an adverse event in this study. 
 
12C2. Adverse Drug Toxicity for Combination therapy pilot study 
An adverse drug toxicity will be defined as any of the following at the 2 or 6 week time point: 
• 
Serious infection qualifying as an SAE (see Section 13) and requiring intervention  
• 
A decrease in the white blood cell count (WBC) to <1500/mm3 (Grade 3 severity by 
NIH/NIAID) (NIH 2009) 
• 
An anaphylactoid reaction to an injection of anakinra 
• 
ALT or AST more than 3x the upper limit of age and sex-adjusted normal AND >50% increase 
over baseline (pre-IVIG) 
• 
CK elevation > 10 times the upper limit of normal or symptoms of muscle pain due to myositis  
• 
A decrease in total cholesterol (TC) level that is at least 10% lower than entry level AND 
below 100 mg/dl (~2.5th percentile for children age 2 yrs.) 
 
A low absolute neutrophil count (ANC) is considered part of the natural course of KD and usually 
occurs 2 weeks after the initial illness (Tremoulet 2011). Given this, a low ANC will not be considered 
an adverse drug toxicity or an adverse event in this study. 
12D. Dose Escalation for the Phase I/IIa anakinra study 
The first 3 subjects in the study will be treated with 4 mg/kg/day as an IV dose of 2 mg/kg q 12 h and 
then as 4 mg/kg/day SQ for 2-6 weeks. If there are no dose limiting toxicities after 2-6 weeks of 
therapy, the safety and clinical data will be tabulated and presented to the PI, co-investigators and 
the Data Safety Monitoring Board (DSMB) for evaluation as to opening the next dose level (6 mg/kg) 
(Tables 5 and 6). Additional subjects will be enrolled at the highest dose if a dose limiting toxicity is 
not reached at 8 mg/kg/day for further study in the Phase IIa (total number of subjects is 30).  
 
Table 6. Dose Escalation Decision Rules 
Subjects with a 
DLT at a Given Dose  
Escalation Decision Rule 
 
0 out of 3 
Enter 3 patients at the next dose level until maximum tolerated dose. 
1 out of 3 
Enter a total of 6 patients at this dose level.  
• If 0 of these additional patients experience a DLT, proceed to the 
next dose level.  
• If 1 of these additional patients experiences a DLT, then dose 
escalation is stopped (see below) 
≥ 2 
At least 3 additional patients will be entered at the next lowest dose 
level if only 3 patients were treated previously at that dose. This lower 
dose level will be declared the MTD. 
 
Probability of Dose Escalation: The following probabilities of dose escalation (Table 7) are computed 
as the sum of the binomial probabilities of the following two possible outcomes that would allow dose 
escalation to occur: (1) no DLT observed in the first three subjects; or (2) one DLT observed in the 
first three subjects, followed by no DLT observed in three additional subjects at the same dose level. 
For example, when the underlying DLT rate is no more than 15%, the probability of dose escalation 
will be at least 81% or alternatively 19% probability of early study termination. Exact 95% binomial 
confidence intervals will be used to describe the rate of successful dose escalation.  

20 
 
 
Table 7: The probabilities for dose escalation in Phase I  
True but unknown DLT rate 
≤0.1 
≤0.15 
≤0.2 
≤0.3 
≤0.4 
Probability of escalation 
≥91% 
≥81% 
≥71% 
≥49% 
≥31% 
 
12E. Maximum Tolerated Dose for Phase I/IIa anakinra study 
The Maximum Tolerated Dose (MTD) will be defined as the highest dose of anakinra studied at which 
no more than one in six patients experiences a DLT during the 6 weeks of treatment. Subjects will be 
enrolled at the maximum tolerated dose until a total of 30 subjects have been enrolled in the study. 
Given the 3+3 design of the study, if there is a DLT then a total of 6 subjects will enrolled per dose 
level. If we reach the 8 mg/kg/day dose level, then up to a maximum of 12 subjects will be enrolled at 
a dose level below the MTD (4 mg/kg and 6 mg/kg). This leaves 18 subjects treated at the MTD if the 
third dosing level is reached. If there are no DLTs at the first two levels, then 3 subjects will be 
enrolled in these two drug levels (total of 6 subjects) leaving 24 subjects to be enrolled at the MTD. 
Thus, between 18 and 24 subjects will be enrolled at the MTD if the 3rd dose level is reached.  
12F. Stopping Rules 
 
 
12F1. Stopping rules for Phase I/IIa anakinra study 
Individual stopping rule: A subject who experiences a DLT will discontinue anakinra immediately 
and will be monitored for resolution of the toxicity as medically appropriate. All subjects will be 
monitored for the 6 weeks from the time of enrollment or until resolution of the DLT, whichever is 
later.  
 
Study stopping rule:  Table 6 shows the Phase I dose escalation rules.  The study will be 
discontinued if at the first dose (4 mg/kg/day), the number of subjects that experiences a DLT is 
greater than 2.  Otherwise, the study will determine its MTD using the escalation rules described.   
 
12F2. Stopping rules for Combination therapy pilot study 
Individual stopping rules:  
A subject who experiences any of the following adverse drug toxicities will discontinue anakinra 
immediately: 
• 
Serious infection qualifying as an SAE (see Section 13) and requiring intervention  
• 
A decrease in the white blood cell count (WBC) to <1500/mm3 (Grade 3 severity by 
NIH/NIAID) (NIH 2009) 
• 
An anaphylactoid reaction to an injection of anakinra  
A subject who experiences any of the following adverse drug toxicities will discontinue atorvastatin 
immediately: 
• 
ALT or AST more than 3x the upper limit of age and sex-adjusted normal AND >50% increase 
over baseline (pre-IVIG) 
• 
CK elevation > 10 times the upper limit of normal or symptoms of muscle pain due to myositis  
• 
A decrease in total cholesterol (TC) level that is at least 10% lower than entry level AND 
below 100 mg/dl (~2.5th percentile for children age 2 yrs.) 
 
Any subject who experiences an adverse drug toxicity that warrants discontinuation of a study drug 
will be monitored for resolution of the toxicity as medically appropriate. All subjects will be monitored 
for 6 weeks from the time of enrollment or until resolution of the adverse drug toxicity, whichever is 
later.  
 

21 
 
Study stopping rule:  The study will be discontinued if three subjects experience adverse drug 
toxicities.   
13. Monitoring Side Effects 
13A. Monitoring side effects for Phase I/IIa anakinra study 
Subjects will be monitored for 6 weeks to evaluate for adverse events (AEs). The main side effect of 
anakinra is an infusion site reaction. The most serious adverse event would be an infection or 
hypersensitivity reaction. All subjects will be monitored for both AEs and SAEs. An AE is any 
unfavorable or unintended change in a sign (i.e. abnormal laboratory), symptom or disease 
temporally associated with the study treatment, whether or not it is considered to be related to the 
study product.   
 
Table 8: Definition of Adverse Events Associated with Anakinra 
Adverse Event 
NOT an Adverse Event (Expected with KD) 
Infusion site reaction 
Atopic dermatitis or psoriasis  
Decrease in WBC as per Table 9 
Eosinophilia (<35%) or ANC (>500) 
Any infection 
Worsening coronary artery dilatation or aneurysm 
compared to baseline 
 
Laboratory values compared to baseline: 
• 
Worsening anemia 
• 
Increasing platelet and lymphocyte counts 
• 
Increasing ESR 
 
 
 
Table 9: Grading Severity of Decrease in WBC Adverse Event (NIH 2009) 
Grade 1 
Mild 
Grade 2 
Moderate 
Grade 3 
Severe 
Grade 4 
Potentially Life 
Threatening 
2,000 – 2,500/mm3 
 
1,500 – 1,999/mm3 
 
1,000 – 1,499/ mm3 
 
< 1,000/mm3 
 
 
A SAE is defined as any event which:  
1. Is fatal; or  
2. Is life-threatening (the patient was, in the view of the Principal Investigator, in immediate danger 
of death from the event as it occurred); or  
3. Requires hospital admission or prolongs hospitalization; or  
4. Is persistent or causing significant disability; or  
5. Required medical intervention, such as major surgery, to prevent a serious outcome; or  
6. The Clinical Site Principal Investigator considers it to be a serious adverse event.  
 
SAEs for this trial include, but are not limited to, anaphylaxis, arrhythmia, cardiac arrest, cardiogenic 
shock, death, hearing loss, hepatitis, hypertension, hypotension, myocardial infarction, renal failure, 
seizures, sepsis (confirmed), or shock.  
 
Any SAE, independent of causality, which occur in a subject in the Trial, assigned to receive Product 
will be reported to Sobi. Reports shall be sent to the Sobi Drug Safety Department by email 
(drugsafety@sobi.com), or by fax (+46 8 697 32 30), within 24 hours of first awareness. Similar 
reporting will occur with the FDA and IRBs as stipulated by their reporting rules. Unanticipated 
problems in involving risk (UPRs) will be reported to each agency as stipulated by their reporting 
rules.  
 
 

22 
 
13B. Monitoring side effects for Combination therapy pilot study 
Subjects will be monitored for 6 weeks to evaluate for AEs. The main side effect of anakinra is an 
infusion site reaction. The most serious adverse event would be an infection or hypersensitivity 
reaction. See Table 8 for definition of AEs associated with anakinra and Table 9 for grading severity 
of a decrease in WBC. Subjects will also be monitored for AEs associated with atorvastatin (Table 
10).  
 
All subjects will be monitored for both AEs and SAEs. An adverse event is any unfavorable or 
unintended change in a sign (i.e. abnormal laboratory), symptom or disease temporally associated 
with the study treatment, whether or not it is considered to be related to the study product.   
 
Table 10: Definition of Adverse Events Associated with Atorvastatin 
ALT or AST more than 3x the upper limit of age and sex-adjusted normal AND >50% increase over 
baseline (pre-IVIG) 
 
CK elevation > 10 times the upper limit of normal or symptoms of muscle pain due to myositis  
 
A decrease in total cholesterol (TC) level that is at least 10% lower than entry level AND below 100 
mg/dl (~2.5th percentile for children age 2 yrs.) 
 
A SAE is defined as any event which:  
1. Is fatal; or  
2. Is life-threatening (the patient was, in the view of the Principal Investigator, in immediate danger 
of death from the event as it occurred); or  
3. Requires hospital admission or prolongs hospitalization; or  
4. Is persistent or causing significant disability; or  
5. Required medical intervention, such as major surgery, to prevent a serious outcome; or  
6. The Clinical Site Principal Investigator considers it to be a serious adverse event.  
 
SAEs for this trial include, but are not limited to, anaphylaxis, arrhythmia, cardiac arrest, cardiogenic 
shock, death, hearing loss, hepatitis, hypertension, hypotension, myocardial infarction, renal failure, 
seizures, sepsis (confirmed), or shock.  
 
Any SAE, independent of causality, which occur in a subject in the Trial, assigned to receive Product 
will be reported to Sobi. Reports shall be sent to the Sobi Drug Safety Department by email 
(drugsafety@sobi.com), or by fax (+46 8 697 32 30), within 24 hours of first awareness. Similar 
reporting will occur with the FDA and IRBs as stipulated by their reporting rules.  
14. Additional Therapy for Phase I/IIa anakinra study and 
Combination therapy pilot study 
14a. Management of Treatment-resistant Subjects 
Treatment-resistance will be defined as persistent or recrudescent fever (T≥38.0˚C rectally) ≥36 
hours and <7 days following end of IVIG infusion. Subjects who meet criteria for treatment-resistance 
will be treated at the Center PI’s discretion.  
14b. Additional Therapy for Coronary Artery Abnormalities  
Additional therapy for coronary artery abnormalities will be at the Center PI’s discretion. A Phase III, 
double-blind, randomized controlled trial of the addition of infliximab to primary treatment with IVIG 
demonstrated that early treatment of infants and children with acute KD with infliximab plus IVIG had 
a more rapid decrease in inflammation, fewer days of fever, and a more rapid decrease in the internal 

23 
 
diameter of a dilated coronary artery compared to IVIG therapy alone (Tremoulet 2014). Thus, 
subjects in this study will be eligible to receive infliximab at the discretion of the Center PI.  
15. Sample Size  
15A. Sample size for Phase I/IIa anakinra study 
A study population of a minimum of 18 KD patients treated with the MTD of anakinra (See Section 
11E for subjects at MTD) and 18 historic matched controls from the Kawasaki Research database 
will have 80% power based on a two-sided, paired t-test to compare change scores from baseline 
between cases and controls with alpha set to 0.05 to detect a minimum difference for the change 
score for several transcript levels of the IL-1 family, including IL-1RAP (pooled SD of 3.2 and 
corresponding difference of 2.2) and IL-1R1 (pooled SD of 8 and corresponding difference of 5.6). 
The effect sizes are based on relevant changes that were found in the largest KD microarray study 
done to date (Hoang 2014). 
 
15B. Sample size for Combination therapy pilot study 
This study is not powered to show a difference in echocardiographic measurements or treatment 
response compared to controls. Instead, the sample size will be determined based on detectable 
differences in inflammatory markers and readouts from in vitro EC studies. A sample size of 10 KD 
patients treated with anakinra/atorvastatin combination therapy vs 10 matched historical controls 
treated with standard therapy alone will have 80% power based on a two-sided, paired t-test with 
alpha set to 0.05 to detect an effect size of 89% in the mean change of EC homeostasis (i.e. markers 
of EndoMT) and inflammasome activation (i.e. TIFA, NLRP3) using the in vitro EC culture system.  
16. Pharmacokinetic Analysis for Phase I/IIa anakinra study 
The area under the concentration-time curve (AUC) around the first dose for anakinra will be roughly 
estimated as the initial concentration (the concentration extrapolated back to time zero) divided by 
the elimination rate, if the elimination appears first-order (log scale) or zero-order (linear scale). We 
will also roughly estimate the AUC using the trapezoidal rule up to the last measurable concentration. 
The extrapolated area after the last concentration will be estimated as Clast/λz, where Clast is the last 
measurable concentration and λz is the terminal slope of the curve. AUC from time 0 to infinity AUC0–
∞ is calculated as AUC0–last + Clast/λz. Noncompartmental oral clearance rate (Cl/FNC) is calculated as 
the ratio of dose to AUC0–∞. Apparent volume of distribution (Vd/FNC) is calculated as Cl/FNC over λz. 
Half-life (t1/2) is calculated as 0.693/λz. Plasma anakinra trough concentrations collected in the 
subacute phase (weeks 2 and 6) will be compared to the 48 hour post-dose concentration collected 
during the acute phase (study day 2). AUC0–∞, Cl/F1-C (oral clearance from 1-compartment model), 
and Vd/F1-C (volume of distribution from 1-compartment model) will also be determined using a 1-
compartment model. This second modeling approach will be used because the data are relatively 
sparse for an intensive PK study, which may limit our ability to estimate every parameter for some 
patients.  
17. Immune Monitoring for Phase I/IIa anakinra study 
PBMC will be separated by Ficoll Hypaque from KD subjects at three time points (pre-treatment, 2 
weeks, and 6 weeks post-treatment) for staining with specific monoclonal antibodies (MoAbs) to 
characterize DC lineages, macrophages and their activation/maturation stage. Anti-DR (MHC class II 
molecules) and anti-CD86 define maturity and activation. CD11c defines the DC lineage, and is not 
expressed on macrophages. Antibodies anti-CD11c will be used in combination with anti-DR and 
anti-CD86 and other markers, well described in the literature. Briefly: to define myeloid DC: anti-
CD11b, (also expressed on macrophages but negative in plasmacytoid DC and thymic DC) and anti-
BDCA-1. To define immature tolerogenic myeloid DC very relevant in the immune-regulation in KD, 
we will look at CD14, co-expressed on macrophages but not on plasmacytoid DC, in CD11c+ CD11b+ 
myeloid DC. Macrophages will be identified by the expression of CD11b and CD14 in CD11c negative 
cells. To enumerate activated CD4+ and CD8+ T cells and regulatory T cells (Treg) we will use anti-

24 
 
CD4, anti-CD8, anti-DR, anti-CD25 (Treg are CD25high) and anti-IL-7 receptor, expressed on pro-
inflammatory cells and peripherally-induced Treg but not in natural Treg. 
18. Measures of Activity  
18A. Measures of inflammation for Phase I/IIa anakinra study  
Transcript abundance will be measured in whole blood by microarray. Levels of hsCRP, α-1-
antitrypsin and fibrinogen, and the WBC and ESR will be measured in the hospital clinical laboratory. 
Levels of TNFaR1 and R2, IFNg, IL-1 RAP, IL-1R1 and R2, MMP9, caspase-1, IL-6R, IL-18RAP, IL-
12, sIL-2R, TGFb and IL-10 will be measured by ELISA. Results of transcript abundance and 
measures of inflammation will be compared to database controls from the KD Research Center (>600 
KD patients with available RNA and plasma samples in our biorepository) matched (1 case: 2 
controls) by age (± 2 yrs. with lower limit of 2 yrs.), sex, and coronary artery Z-score.  
 
18B. Measures of inflammation and endothelial cell function for Combination therapy 
pilot study 
We will measure plasma levels of IL-1R accessory protein and soluble IL-1R1 from the study 
subjects and controls as surrogates for IL-1α and IL-1β, which are not stable in patient plasma. To 
further assess inflammation, we will also measure the following pro-inflammatory cytokines in 
plasma: IL-17, IL-6, sIL-6R, TNFαR1, IFNγ, as well as the anti-inflammatory cytokine IL-10. To 
assess the change in MMP9 activity that could be a direct effect of atorvastatin treatment,(Koh 2002, 
Massaro 2010) we will measure plasma MMP9 levels. Transcript levels in whole blood RNA 
(PAXgene® tubes) of all of the above analytes will be measured using a combination of TaqMan 5'-
nuclease Gene Expression Assays (Applied Biosystems) and the Inflammatory cytokine array 
(Qiagen). Relative abundance of the target transcripts will be normalized to the expression level of 
TAF1B, which has been validated as a housekeeping gene that is not upregulated in acute 
KD.(Popper 2007) Time points for all of the above studies will be baseline, 48 hr, and 2 wk post-
treatment. Three different control groups with samples collected at similar time points will be matched 
from our KD biorepository at UCSD (>600 subjects): standard treatment alone (n=20), standard 
treatment+atorvastatin (n=10), and standard treatment+anakinra (n=10). Banked samples, including 
those from Phase I trials of both anakinra and atorvastatin, will allow us to match study patients on 
potentially important variables including age, sex, illness day at diagnosis, and baseline coronary 
artery damage as measured by echocardiogram. 
 
Subject and control sera will be compared for suppression of the innate immune response by 
anakinra and restoration of EC function by atorvastatin. IL-1-TIFA-NLRP3 activation as well as levels 
of KLF4, miR-483, and EndoMT marker genes including CTGF in cultured human aortic ECs and 
mouse lung ECs with subject and control sera from baseline, 48 hr, and 2 wk post-treatment will be 
measured. Functional assays will also be performed including NO bioavailability and EC permeability. 
Induction of EndoMT will be compared using paired sera from pre-treatment and 2 wk time points 
while induction of an EC inflammatory response will be compared using pre-treatment and 48 hr 
post-treatment paired sera. These readouts of innate immune activation and EC function will be 
correlated with clinical data.  
19. Statistical Analyses 
19A. Statistical analysis of safety for Phase I/IIa anakinra study and 
Combination therapy pilot study 
Descriptive statistics will be calculated for demographic and baseline characteristics, variables 
related to biologic activity, immunologic variables, PK variables, and safety data. The study 
population will be described using summary descriptive statistics such as mean, median, standard 
deviation, and range for continuous variables and frequencies for categorical variables. All events 
(AEs, SAEs, and UPRs) will be recorded, documenting the course, outcome, severity, and 

25 
 
relationship to the study treatment. Incidence rates of events and the proportion of subjects 
prematurely withdrawn from the study due to events will be compiled. Analyses will be performed for 
all patients who have received at least one dose of study treatment. Deviation from the treatment 
plan will be recorded in the case report forms. The percentage of subjects failing to complete the 
study or discontinuing prematurely (as well as the times and reasons for discontinuation) will be 
reported.  Refer to Section 12E for the operating characteristics of the Phase I dose escalation for the 
Phase I/IIa anakinra study. 
19B. Statistical analysis of inflammatory studies 
19B1. Statistical analysis of inflammation studies for Phase I/IIa anakinra study 
The objective of this matched case-control study is to determine the activity profile of anakinra in the 
treatment of KD subjects with CAA. Measures of inflammation will be compared to that of matched 
controls via paired statistical tests (e.g. McNemar’s test for categorical outcomes or the paired t-test 
for continuous outcomes). Non-parametric alternatives will be considered only if distributional 
assumptions are violated. 
 
Control Group: Controls will be chosen from the >600 subjects with data in our web-based data 
repository in REDCap. Controls will be matched to study patients based on age, sex, Illness Day at 
diagnosis, and baseline Z score. 
 
Analysis: Each marker will be initially summarized descriptively and analyzed individually. Separate 
multivariable mixed effects regression modeling for clustered data (to account for the case-control 
paired nature of samples) will be used to characterize the markers of anakinra-treated subjects 
versus matched controls to adjust for any known confounders and additional time points (baseline, 48 
hours, 2 weeks, and 6 weeks). In addition, any covariate at the individual level that is simultaneously 
unbalanced and associated with the outcome will be included in the model. Covariates of interest 
include demographic variables (e.g., ethnicity, Illness Day at diagnosis, response to IVIG therapy). 
Permutation tests may be implemented to verify that valid p-values will be obtained even if model 
assumptions are not correct. Note that the mixed model seamlessly accommodates different times of 
measurement (e.g. 2-week and 6-week time points) as well as missed measurements and data from 
subjects who are lost to follow-up. A corresponding Generalized Estimating Equations (GEE) model 
will be used as the sensitivity analysis method.  An analogous secondary model including all subjects 
in this study will also be considered to examine the dose versus activity relationship. In this model, 
dosage will be included as a covariate to examine any dosage trend in activity.  
 
The above approach will be repeated for the other markers. That is, multi-level mixed effects 
regression models analogous to the above methodology will be applied for other markers: Levels of 
high sensitivity (hs) CRP, alpha-1 antitrypsin, TNFaR1 and R2, IFNg, IL-1 RAP, IL-1R1 and R2, 
MMP9, caspase-1, IL-6R, IL-18RAP, IL-12, IL-2, TGFb and IL-10.  
 
Measures of transcript abundance will also be analyzed via microarray analysis. Data will be pre-
processed first and then microarray analysis procedures will be used to measure abundance.  The R 
software (version 3.0.2) and Bioconductor package in R will be used for the analysis. For coronary 
outcomes as assessed by echocardiography, we will compare the delta Z scores (baseline minus 2-
weeks and 6-weeks) between anakinra subjects and matched controls. A GEE model will be used as 
the sensitivity analysis method. Since this is a safety and early efficacy study, no adjustments for 
multiple comparisons will be made for biomarker analyses. P-values less than 0.05 will be considered 
statistically significant.  All statistical analyses will be performed in R version 3.2.0 (www.r-
project.org/).  Similarly, analyses will be repeated on all subjects to characterize any dose-activity 
relationship, adjusting for dosage as a covariate in the model. 
 
To determine the “best” or “set of best” markers that have the greatest improvement from baseline in 
anakinra-treated patients, ROC and AUROC analysis will be considered.  In the event that there is 

26 
 
high multi-collinearity amongst the markers, we will adopt the “glmpath” approach, which is based on 
Least Angle Regression (LARS) methods to select the best biomarkers (Park 2007).  
 
Missing data assumptions: The proposed mixed-effects regression model is consistent under the 
assumption that the outcome data are “missing at random” (MAR), that is, mixed models with a 
random effect assume only that the probability that an outcome is missing depends on observed 
outcomes. GEE models, which are proposed as a sensitivity analysis, assume that the outcome data 
are “missing completely at random”, that is, that the probability that an outcome is missing does not 
depend on any previous, present or succeeding value of the outcome. This will enable us to assess 
the impact of the missing data mechanism on statistical inferences drawn from these models.   
 
19B2. Statistical analysis of inflammation and endothelial cell studies for Combination 
therapy pilot study 
 
The objective of this matched case-control study is to determine the activity profile of the combination 
of anakinra and atorvastatin in the treatment of KD subjects with CAA. Measures of inflammation and 
endothelial cell function will be compared to that of matched controls via paired statistical tests (e.g. 
McNemar’s test for categorical outcomes or the paired t-test for continuous outcomes). Non-
parametric alternatives will be considered only if distributional assumptions are violated. 
 
Control Group: Controls will be chosen from the >600 subjects with data in our web-based data 
repository in REDCap. Controls will be matched to study patients based on age, sex, illness day at 
diagnosis, and baseline Z score. 
 
Analysis: Each marker will be initially summarized descriptively and analyzed individually. Separate 
multivariable mixed effects regression modeling for clustered data (to account for the case-control 
paired nature of samples) will be used to characterize the markers of treated subjects versus 
matched controls to adjust for any known confounders and additional time points (baseline, 48 hours, 
2 weeks, and 6 weeks). In addition, any covariate at the individual level that is simultaneously 
unbalanced and associated with the outcome will be included in the model. Covariates of interest 
include demographic variables (e.g., ethnicity, Illness Day at diagnosis, response to IVIG therapy). 
Permutation tests may be implemented to verify that valid p-values will be obtained even if model 
assumptions are not correct. Note that the mixed model seamlessly accommodates different times of 
measurement (e.g. 48h and 2-week time points) as well as missed measurements and data from 
subjects who are lost to follow-up. A corresponding Generalized Estimating Equations (GEE) model 
will be used as the sensitivity analysis method. To determine the “best” or “set of best” markers that 
have the greatest improvement from baseline in anakinra/atorvastatin-treated patients, ROC and 
AUROC analysis will be considered to choose the best of set markers for a future clinical trial. In the 
event that there is high multicollinearity amongst the markers, we will adopt the “glmpath” approach, 
which is based on Least Angle Regression (LARS) methods to select the best biomarkers.(Park 
2007)  
 
Measures of transcript abundance will also be analyzed via RNAseq. The R software (version 3.0.2) 
and Bioconductor package in R will be used for the analysis. For coronary outcomes as assessed by 
echocardiography, we will compare the delta Z scores (baseline minus 2-weeks and 6-weeks) 
between anakinra subjects and matched controls. A GEE model will be used as the sensitivity 
analysis method. Since this is a pilot study, no adjustments for multiple comparisons will be made for 
biomarker analyses. P-values less than 0.05 will be considered statistically significant.  All statistical 
analyses will be performed in R version 3.2.0 (www.r-project.org/).   
 
Missing data assumptions: The proposed mixed-effects regression model is consistent under the 
assumption that the outcome data are “missing at random” (MAR), that is, mixed models with a 
random effect assume only that the probability that an outcome is missing depends on observed 
outcomes. GEE models, which are proposed as a sensitivity analysis, assume that the outcome data 
are “missing completely at random”, that is, that the probability that an outcome is missing does not 

27 
 
depend on any previous, present or succeeding value of the outcome. This will enable us to assess 
the impact of the missing data mechanism on statistical inferences drawn from these models.   
20. Data and Safety Monitoring  
20A. Data and Safety Monitoring Board (DSMB) for Phase I/IIa anakinra study  
As a first step in assuring the safety of subjects participating in this trial, monthly conference calls 
with the study nurse, PI, and co-investigators will be conducted to discuss progress of the trial and 
possible safety issues. Safety and clinical data will be tabulated and presented to the PI and co-
investigators by the study biostatistician for discussion prior to opening the next dose level. The 
DSMB, a panel consisting of outside experts, including one clinician with expertise in KD, a 
pharmacologist, and a biostatistician, in collaboration with the Study Investigators, will pre-specify a 
plan for evaluating the data on a periodic basis and will set up pre-specified stopping rules for safety. 
20B. Data and Safety Monitoring Plan (DSMP) for Combination therapy pilot 
study 
As this is a study that involves children and the investigators must protect this vulnerable population, 
a DSMP has been established. To assure the safety of subjects participating in this trial, Drs. Burns 
and Tremoulet will meet after enrollment of every 2 subjects to discuss progress of the trial and 
possible safety issues. Safety and clinical data will be tabulated and presented by the biostatistician 
to the investigators after five subjects have been enrolled and at the end of the study. An earlier 
meeting can be convened by Dr. Tremoulet, Dr. Burns or Dr. Jain if safety questions or other 
unanticipated problems arise.  
 
The UCSD IRB, FDA, Pfizer and Sobi Pharmaceuticals will be immediately notified (within 48h) of 
any UPRs. For anticipated SAEs and AEs, the UCSD IRB will receive a report as per their reporting 
guidelines. 
  

28 
 
Appendix A: Preparation of Anakinra (Kineret®) in the Hospital for 
Doses < 20 mg 
 
 
The following protocol is completed using a single dose, pre-filled syringe of 
commercially available Kineret® (100 mg/0.67ml syringe) by a pharmacist or 
pharmacy technician who is gowned and gloved, and is wearing a cap, face mask, and 
shoe covers. 
 
1. Aseptically transfer the anakinra directly into a sterile one ml syringe in an ISO Class 5 IV 
hood located in the hospital inpatient pharmacy IV Class 10,000 clean room.  
 
2. The prepared dose syringe is then capped and labeled and given a 4-hour expiration under 2-
8C refrigerated.  
 

29 
 
 
 
References: 
 
Aksentijevich, I., S. L. Masters, P. J. Ferguson, P. Dancey, J. Frenkel, A. van Royen-Kerkhoff, R. 
Laxer, U. Tedgard, E. W. Cowen, T. H. Pham, M. Booty, J. D. Estes, N. G. Sandler, N. Plass, D. L. 
Stone, M. L. Turner, S. Hill, J. A. Butman, R. Schneider, P. Babyn, H. I. El-Shanti, E. Pope, K. 
Barron, X. Bing, A. Laurence, C. C. Lee, D. Chapelle, G. I. Clarke, K. Ohson, M. Nicholson, M. 
Gadina, B. Yang, B. D. Korman, P. K. Gregersen, P. M. van Hagen, A. E. Hak, M. Huizing, P. 
Rahman, D. C. Douek, E. F. Remmers, D. L. Kastner and R. Goldbach-Mansky (2009). "An 
autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist." N Engl J Med 
360(23): 2426-2437.PMCID: 2876877. 
Cartwright, V. (2014). Personal communication regarding treatment with anakinra. 
Chaudhuri, K., T. Singh Ahluwalia, S. Singh, G. Binepal and M. Khullar "Polymorphism in the 
promoter of the CCL5 gene (CCL5G-403A) in a cohort of North Indian children with Kawasaki 
disease. A preliminary study." Clin Exp Rheumatol. 
Cohen, S., C. E. Tacke, B. Straver, N. Meijer, I. M. Kuipers and T. W. Kuijpers (2012). "A child with 
severe relapsing Kawasaki disease rescued by IL-1 receptor blockade and extracorporeal membrane 
oxygenation." Ann Rheum Dis 71(12): 2059-2061. 
Collins, F. S. (2011). "Mining for therapeutic gold." Nature reviews. Drug discovery 10(6): 397. 
Daniels, L., M. Tjajadi, H. Walford, D. Fick, H. Phan, P. Linz, K. Nayak, A. Kahn, J. Burns and J. 
Gordon (2012). "Prevalence of Kawasaki Disease in Young Adults with Suspected Myocardial 
Ischemia." Circulation 125(20): 2447-2453. 
Ea, C. K., L. Sun, J. Inoue and Z. J. Chen (2004). "TIFA activates IkappaB kinase (IKK) by 
promoting oligomerization and ubiquitination of TRAF6." Proc Natl Acad Sci U S A 101(43): 15318-
15323.PMCID: PMC524439. 
Gordon, J. B., A. M. Kahn and J. C. Burns (2009). "When children with kawasaki disease grow up 
myocardial and vascular complications in adulthood." J Am Coll Cardiol 54(21): 1911-1920. 
Gordon, J. B., A. M. Kahn and J. C. Burns (2009). "When children with kawasaki disease grow up 
myocardial and vascular complications in adulthood." Journal of the American College of Cardiology 
54(21): 1911-1920.PMCID: 2870533. 
Guedes, M. (2014). "Personal communication regarding treatment with anakinra." 
Harris, P. A., R. Taylor, R. Thielke, J. Payne, N. Gonzalez and J. G. Conde (2009). "Research 
electronic data capture (REDCap)--a metadata-driven methodology and workflow process for 
providing translational research informatics support." J Biomed Inform 42(2): 377-381.PMCID: 
2700030. 
He, M., Z. Chen, M. Martin, J. Zhang, P. Sangwung, B. Woo, A. H. Tremoulet, C. Shimizu, M. K. 
Jain, J. C. Burns and J. Y. Shyy (2017). "miR-483 Targeting of CTGF Suppresses Endothelial-to-
Mesenchymal Transition: Therapeutic Implications in Kawasaki Disease." Circ Res 120(2): 354-365. 
Hoang, L. T., C. Shimizu, L. Ling, A. N. Naim, C. C. Khor, A. H. Tremoulet, V. Wright, M. Levin, 
M. L. Hibberd and J. C. Burns (2014). "Global gene expression profiling identifies new therapeutic 
targets in acute Kawasaki disease." Genome Med 6(11): 541.PMCID: 4279699. 
Hoffman, H. M. (2009). "Therapy of autoinflammatory syndromes." The Journal of allergy and 
clinical immunology 124(6): 1129-1138; quiz 1139-1140. 
Hoffman, H. M. (2014). Personal communication regarding treatment with anakinra. 
Huang, C. C., J. H. Weng, T. Y. Wei, P. Y. Wu, P. H. Hsu, Y. H. Chen, S. C. Wang, D. Qin, C. C. 
Hung, S. T. Chen, A. H. Wang, J. Y. Shyy and M. D. Tsai (2012). "Intermolecular binding between 
TIFA-FHA and TIFA-pT mediates tumor necrosis factor alpha stimulation and NF-kappaB 
activation." Mol Cell Biol 32(14): 2664-2673.PMCID: PMC3416184. 

30 
 
Jerath, R. (2014). "Personal communication regarding treatment with anakinra." 
Kaneko, K., K. Yoshimura, A. Ohashi, T. Kimata, T. Shimo and S. Tsuji (2011). "Prediction of the 
risk of coronary arterial lesions in Kawasaki disease by brain natriuretic peptide." Pediatr Cardiol 
32(8): 1106-1109. 
Kato, H., T. Sugimura, T. Akagi, N. Sato, K. Hashino, Y. Maeno, T. Kazue, G. Eto and R. Yamakawa 
(1996). "Long-term consequences of Kawasaki disease. A 10- to 21-year follow-up study of 594 
patients." Circulation 94(6): 1379-1385. 
Kato, T., A. Numaguchi, H. Ando, M. Yasui, Y. Kishimoto, K. Yasuda, D. Fukumi and T. Yasuda 
"Coronary arterial ectasia in a 2-year-old boy showing two symptoms of Kawasaki disease without 
manifesting fever." Rheumatol Int. 
Koh, K. K., J. W. Son, J. Y. Ahn, D. K. Jin, H. S. Kim, Y. M. Choi, D. S. Kim, E. M. Jeong, G. S. 
Park, I. S. Choi and E. K. Shin (2002). "Comparative effects of diet and statin on NO bioactivity and 
matrix metalloproteinases in hypercholesterolemic patients with coronary artery disease." Arterioscler 
Thromb Vasc Biol 22(9): e19-23. 
Kuemmerle-Deschner, J. B., P. N. Tyrrell, I. Koetter, H. Wittkowski, A. Bialkowski, N. Tzaribachev, 
P. Lohse, A. Koitchev, C. Deuter, D. Foell and S. M. Benseler (2011). "Efficacy and safety of 
anakinra therapy in pediatric and adult patients with the autoinflammatory Muckle-Wells syndrome." 
Arthritis Rheum 63(3): 840-849. 
Lee, Y., D. J. Schulte, K. Shimada, S. Chen, T. R. Crother, N. Chiba, M. C. Fishbein, T. J. Lehman 
and M. Arditi (2012). "Interleukin-1beta is crucial for the induction of coronary artery inflammation 
in a mouse model of Kawasaki disease." Circulation 125(12): 1542-1550.PMCID: 3337219. 
Leung, D. Y., R. S. Cotran, E. Kurt-Jones, J. C. Burns, J. W. Newburger and J. S. Pober (1989). 
"Endothelial cell activation and high interleukin-1 secretion in the pathogenesis of acute Kawasaki 
disease." Lancet 2(8675): 1298-1302. 
Levy, M., A. Arion, D. Berrebi, L. Cuisset, C. Jeanne-Pasquier, B. Bader-Meunier and C. Jung 
(2013). "Severe early-onset colitis revealing mevalonate kinase deficiency." Pediatrics 132(3): e779-
783. 
Liao, J. K. and U. Laufs (2005). "Pleiotropic effects of statins." Annu Rev Pharmacol Toxicol 45: 89-
118.PMCID: PMC2694580. 
Lin, T. Y., T. W. Wei, S. Li, S. C. Wang, M. He, M. Martin, J. Zhang, T. P. Shentu, H. Xiao, J. Kang, 
K. C. Wang, Z. Chen, S. Chien, M. D. Tsai and J. Y. Shyy (2016). "TIFA as a crucial mediator for 
NLRP3 inflammasome." Proc Natl Acad Sci U S A 113(52): 15078-15083.PMCID: PMC5206521. 
Manlhiot, C., K. Millar, F. Golding and B. W. McCrindle (2009). "Improved Classification of 
Coronary Artery Abnormalities Based Only on Coronary Artery z-Scores After Kawasaki Disease." 
Pediatr Cardiol. 
Massaro, M., A. Zampolli, E. Scoditti, M. A. Carluccio, C. Storelli, A. Distante and R. De Caterina 
(2010). "Statins inhibit cyclooxygenase-2 and matrix metalloproteinase-9 in human endothelial cells: 
anti-angiogenic actions possibly contributing to plaque stability." Cardiovasc Res 86(2): 311-320. 
Matsubara, T., M. Hasegawa, M. Shiraishi, H. M. Hoffman, T. Ichiyama, T. Tanaka, H. Ueda, T. 
Ishihara and S. Furukawa (2006). "A severe case of chronic infantile neurologic, cutaneous, articular 
syndrome treated with biologic agents." Arthritis and Rheumatism 54(7): 2314-2320. 
Maury, C. P., E. Salo and P. Pelkonen (1988). "Circulating interleukin-1 beta in patients with 
Kawasaki disease." N Engl J Med 319(25): 1670-1671. 
Minkis, K., I. Aksentijevich, R. Goldbach-Mansky, C. Magro, R. Scott, J. G. Davis, N. Sardana and 
R. Herzog (2012). "Interleukin 1 receptor antagonist deficiency presenting as infantile pustulosis 
mimicking infantile pustular psoriasis." Archives of Dermatology 148(6): 747-752.PMCID: 3474848. 
Momborquette, J. L. (2014). "Personal communication regarding treatment with anakinra." 
Montealegre, G. (2014). Personal communication regarding treatment with anakinra. 

31 
 
Nakamura, Y., M. Yashiro, R. Uehara, A. Sadakane, I. Chihara, Y. Aoyama, K. Kotani and H. 
Yanagawa (2010). "Epidemiologic Features of Kawasaki Disease in Japan: Results of the 2007-2008 
Nationwide Survey." J Epidemiol. 
Neven, B., I. Marvillet, C. Terrada, A. Ferster, N. Boddaert, V. Couloignier, G. Pinto, A. Pagnier, C. 
Bodemer, B. Bodaghi, M. Tardieu, A. M. Prieur and P. Quartier (2010). "Long-term efficacy of the 
interleukin-1 receptor antagonist anakinra in ten patients with neonatal-onset multisystem 
inflammatory disease/chronic infantile neurologic, cutaneous, articular syndrome." Arthritis and 
Rheumatism 62(1): 258-267. 
Newburger, J. W., M. Takahashi, M. A. Gerber, M. H. Gewitz, L. Y. Tani, J. C. Burns, S. T. Shulman, 
A. F. Bolger, P. Ferrieri, R. S. Baltimore, W. R. Wilson, L. M. Baddour, M. E. Levison, T. J. Pallasch, 
D. A. Falace and K. A. Taubert (2004). "Diagnosis, treatment, and long-term management of 
Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, 
Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American 
Heart Association." Circulation 110(17): 2747-2771. 
Nigrovic, P. A., M. Mannion, F. H. Prince, A. Zeft, C. E. Rabinovich, M. A. van Rossum, E. Cortis, 
M. Pardeo, P. M. Miettunen, G. Janow, J. Birmingham, A. Eggebeen, E. Janssen, A. I. Shulman, M. 
B. Son, S. Hong, K. Jones, N. T. Ilowite, R. Q. Cron and G. C. Higgins (2011). "Anakinra as first-line 
disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an 
international multicenter series." Arthritis and Rheumatism 63(2): 545-555. 
NIH and DAIDS. (2009). "Division of AIDS Table for Grading the Severity of Adult and Pediatric 
Adverse Events." from 
http://www.niaid.nih.gov/LabsAndResources/resources/DAIDSClinRsrch/Documents/daidsaegradingt
able.pdf. 
Nishiike, S., M. Nagai, A. Nakagawa, M. Konishi, Y. Sakata, T. Aihara and T. Harada (2006). 
"Laryngeal tuberculosis following laryngeal carcinoma." J Laryngol Otol 120(2): 151-153. 
Oesterle, A., U. Laufs and J. K. Liao (2017). "Pleiotropic Effects of Statins on the Cardiovascular 
System." Circ Res 120(1): 229-243. 
Ombrello, A. (2014). "Personal communication regarding treatment with anakinra." 
Opal, S. M., C. J. Fisher, Jr., J. F. Dhainaut, J. L. Vincent, R. Brase, S. F. Lowry, J. C. Sadoff, G. J. 
Slotman, H. Levy, R. A. Balk, M. P. Shelly, J. P. Pribble, J. F. LaBrecque, J. Lookabaugh, H. 
Donovan, H. Dubin, R. Baughman, J. Norman, E. DeMaria, K. Matzel, E. Abraham and M. Seneff 
(1997). "Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, 
double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis 
Investigator Group." Crit Care Med 25(7): 1115-1124. 
Park, M. Y. and T. Hastie (2007). "L1 regularization path algorithm for generalized linear models." J 
R Statist Soc 69: 659-677. 
Popper, S. J., C. Shimizu, H. Shike, J. T. Kanegaye, J. W. Newburger, R. P. Sundel, P. O. Brown, J. 
C. Burns and D. A. Relman (2007). "Gene-expression patterns reveal underlying biological processes 
in Kawasaki disease." Genome biology 8(12): R261.PMCID: 2246263. 
Printz, B. F., L. A. Sleeper, J. W. Newburger, L. L. Minich, T. Bradley, M. S. Cohen, D. Frank, J. S. 
Li, R. Margossian, G. Shirali, M. Takahashi and S. D. Colan "Noncoronary cardiac abnormalities are 
associated with coronary artery dilation and with laboratory inflammatory markers in acute kawasaki 
disease." J Am Coll Cardiol 57(1): 86-92. 
Punaro, M. (2014). "Personal communication regarding treatment with anakinra." 
Ravekes, W. J., S. D. Colan, K. Gauvreau, A. L. Baker, R. P. Sundel, M. E. van der Velde, D. R. 
Fulton and J. W. Newburger (2001). "Aortic root dilation in Kawasaki disease." Am J Cardiol 87(7): 
919-922. 
Record, J. L., T. Beukelman and R. Q. Cron (2011). "Combination therapy of abatacept and anakinra 
in children with refractory systemic juvenile idiopathic arthritis: a retrospective case series." Journal 
of Rheumatology 38(1): 180-181. 

32 
 
Ringold, S., P. F. Weiss, T. Beukelman, E. M. DeWitt, N. T. Ilowite, Y. Kimura, R. M. Laxer, D. J. 
Lovell, P. A. Nigrovic, A. B. Robinson and R. K. Vehe (2013). "2013 update of the 2011 American 
College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: 
recommendations for the medical therapy of children with systemic juvenile idiopathic arthritis and 
tuberculosis screening among children receiving biologic medications." Arthritis Rheum 65(10): 
2499-2512. 
Rossi-Semerano, L., M. Piram, C. Chiaverini, D. De Ricaud, A. Smahi and I. Kone-Paut (2013). "First 
clinical description of an infant with interleukin-36-receptor antagonist deficiency successfully treated 
with anakinra." Pediatrics 132(4): e1043-1047. 
Ruiz Gomez, A., M. L. Couce, J. Garcia-Villoria, A. Torres, A. Bana Souto, J. Yague, M. A. Vilaseca, 
A. Ribes and J. I. Arostegui (2012). "Clinical, genetic, and therapeutic diversity in 2 patients with 
severe mevalonate kinase deficiency." Pediatrics 129(2): e535-539. 
Shafferman, A., J. D. Birmingham and R. Q. Cron (2014). "High dose anakinra for treatment of severe 
neonatal Kawasaki disease: a case report." Pediatr Rheumatol Online J 12: 26.PMCID: 4103976. 
Shimizu, C., T. Oharaseki, K. Takahashi, A. Kottek, A. Franco and J. C. Burns (2013). "The role of 
TGF-beta and myofibroblasts in the arteritis of Kawasaki disease." Human Pathology 44(2): 189-
198.PMCID: 3518690. 
Sibley, C. H., N. Plass, J. Snow, E. A. Wiggs, C. C. Brewer, K. A. King, C. Zalewski, H. J. Kim, R. 
Bishop, S. Hill, S. M. Paul, P. Kicker, Z. Phillips, J. G. Dolan, B. Widemann, N. Jayaprakash, F. 
Pucino, D. L. Stone, D. Chapelle, C. Snyder, J. A. Butman, R. Wesley and R. Goldbach-Mansky 
(2012). "Sustained response and prevention of damage progression in patients with neonatal-onset 
multisystem inflammatory disease treated with anakinra: a cohort study to determine three- and five-
year outcomes." Arthritis Rheum 64(7): 2375-2386.PMCID: 3474541. 
Stenerson, M., K. Dufendach, I. Aksentijevich, J. Brady, J. Austin and A. M. Reed (2011). "The first 
reported case of compound heterozygous IL1RN mutations causing deficiency of the interleukin-1 
receptor antagonist." Arthritis and Rheumatism 63(12): 4018-4022. 
Tremoulet, A. H., B. M. Best, S. Song, S. Wang, E. Corinaldesi, J. R. Eichenfield, D. D. Martin, J. W. 
Newburger and J. C. Burns (2008). "Resistance to intravenous immunoglobulin in children with 
Kawasaki disease." J Pediatr 153(1): 117-121.PMCID: 2526555. 
Tremoulet, A. H., S. Jain and J. C. Burns (2015). "Evaluating a novel treatment for coronary artery 
inflammation in acute Kawasaki disease: A Phase I/IIa trial of atorvastatin." Expert Opin Orphan 
Drugs 3(9): 967-970.PMCID: PMC4979608. 
Tremoulet, A. H., S. Jain, D. Chandrasekar, X. Sun, Y. Sato and J. C. Burns (2011). "Evolution of 
laboratory values in patients with Kawasaki disease." The Pediatric Infectious Disease Journal 30(12): 
1022-1026.PMCID: 3222731. 
Tremoulet, A. H., S. Jain, P. Jaggi, S. Jimenez-Fernandez, J. M. Pancheri, X. Sun, J. T. Kanegaye, J. 
P. Kovalchin, B. F. Printz, O. Ramilo and J. C. Burns (2014). "Infliximab for intensification of 
primary therapy for Kawasaki disease: a phase 3 randomised, double-blind, placebo-controlled trial." 
Lancet 383(9930): 1731-1738. 
Urien, S., C. Bardin, B. Bader-Meunier, R. Mouy, S. Compeyrot-Lacassagne, F. Foissac, B. Florkin, 
C. Wouters, B. Neven, J. M. Treluyer and P. Quartier (2013). "Anakinra pharmacokinetics in children 
and adolescents with systemic-onset juvenile idiopathic arthritis and autoinflammatory syndromes." 
BMC Pharmacol Toxicol 14(1): 40.PMCID: 3750485. 
Yonesaka, S., T. Nakada, Y. Sunagawa, K. Tomimoto, S. Naka, T. Takahashi, T. Matubara and I. 
Sekigami (1989). "Endomyocardial biopsy in children with Kawasaki disease." Acta Paediatr Jpn 
31(6): 706-711. 
Yutani, C., K. Okano, T. Kamiya, K. Oguchi, T. Kozuka, M. Ota and S. Onishi (1980). 
"Histopathological study on right endomyocardial biopsy of Kawasaki disease." Br Heart J 43(5): 
589-592.